Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bromocriptine therapy for hyperthyroidism due to increased thyrotropin secretion.

J Takamatsu, T Mozai, K Kuma

    The Journal of Clinical Endocrinology and Metabolism
    |May 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Factor IX inhibition and epitope localization of factor IX inhibitor antibodies in haemophilia B patients with anaphylactoid reactions.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.

    Haemophilia : the official journal of the World Federation of Hemophilia·2013
    Same author

    Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.

    Haemophilia : the official journal of the World Federation of Hemophilia·2012
    Same author

    An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.

    Haemophilia : the official journal of the World Federation of Hemophilia·2011
    Same author

    Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial.

    Haemophilia : the official journal of the World Federation of Hemophilia·2011

    This study presents a case of hyperthyroidism caused by excessive thyroid-stimulating hormone (TSH) secretion, successfully treated with bromocriptine. The drug normalized TSH and prolactin levels, resolving hyperthyroid symptoms.

    Area of Science:

    • Endocrinology
    • Neuroendocrinology

    Background:

    • Hyperthyroidism can arise from various causes, including inappropriate thyroid-stimulating hormone (TSH) secretion.
    • Pituitary adenomas are a common cause of TSH-induced hyperthyroidism, but other mechanisms exist.

    Observation:

    • A 25-year-old woman presented with hyperthyroidism and elevated serum T4, T3, TSH, and prolactin (PRL) levels.
    • No pituitary tumor was identified, suggesting a non-adenomatous cause for excessive TSH secretion.

    Findings:

    • Bromocriptine treatment for 4 months normalized serum TSH and PRL levels.
    • Concurrently, serum T3 and T4 levels decreased, and hyperthyroid symptoms regressed.

    Implications:

    • This case suggests that altered hypothalamic dopaminergic tone may contribute to TSH-induced hyperthyroidism.

    Related Experiment Videos

  • Bromocriptine may be a viable therapeutic option for TSH-induced hyperthyroidism without pituitary tumors.